September 26th, 2017

Dr. Engin Altıntaş
Mersin University Medical Faculty
Internal Medicine Department
Mersin Üniversitesi Tıp Fakultesi Hastanesi
İç hastalıkları Anabilim Dalı
Mersin, Turkey-33343

RE: Allergan D5170C00002: Notification of Study Termination

ALLERGAN: D5170C00002, A Phase 2b Double-blind, Multi-dose, Placebo-controlled Study to Evaluate the Efficacy and Safety of MEDI2070 in Subjects with Moderate to Severe Crohn's Disease Who Have Failed or Are Intolerant to Anti-tumor Necrosis Factor-alpha Therapy (the "Study")

Dear Dr. Engin Altıntaş,

As you are aware, screening of new patients for the Study was placed on hold in May 2017 to allow Allergan the opportunity to assess the feasibility of implementing significant changes to the Study design. After further consideration, it has been determined that it would not be appropriate to implement these substantial changes via a protocol amendment and a decision has been made to terminate the Study. It is important to note that Allergan remains committed to the MEDI2070/Brazikumab program and the termination of the Study will allow us to redesign and start a new study in the near future. Key changes that are under consideration include higher doses tested against an active comparator in all-comers, an earlier primary endpoint and longer open-label period.

We have enjoyed working with you and your site, and this decision does not, in any way, reflect on your site's performance or qualifications, or on the safety or expected efficacy of MEDI2070/Brazikumab.

Your Quintiles Clinical Research Associate (CRA) will be in touch with you shortly to discuss any necessary arrangements for the patient's Early Termination visit, and the close out of the Study at your site. Please note per your site contract that all patient data should be entered into InForm within two weeks for screen failed patients, 3 weeks for randomized patients, as all data captured to date during the Study will be analyzed and reported. Also, continue to answer all InForm and vendor data queries. Allergan/ Quintiles will be making the necessary submissions to the Regulatory Authorities and to Central Ethics Committees. All local Ethics Committee submissions should be made by you if necessary.

Please be advised that this notification and the information contained herein should be deemed confidential and is subject to the confidentiality obligations as set forth in your clinical trial agreement/confidentiality agreement. As such this information should only be shared with study personnel working on the Study.

Allergan greatly appreciates all the work you and your site staff have done on behalf of the Study. Good clinical research depends on dedicated sites like yours and we thank you for your great work and understanding. We hope that you will continue to be interested in participating in future MEDI2070/Brazikumab studies, as we continue our journey with this exciting compound to make a difference in patients' lives. Please feel free to contact us if you have questions or comments.

Yours sincerely

Carl Gommoll, MS
Associate Vice President, Clinical Development
Global Brands Research and Development
185 Hudson Street, Suite 1900
Jersey City, NJ 07311
Phone: (201)-427-8124
Mobile: (609)-203-7783
carl.gommoll@allergan.com

Cathleen Platt
Associate Vice President
Global Clinical Trial, GI
185 Hudson Street,
Jersey City, NJ 07311
Phone: (201)-427-8003
Mobile: 973-722-3758
Cathleen.Platt@Allergan.com